Karo Pharma AB ("Karo Pharma") has today successfully completed the voluntary offer for Weifa ASA ("Weifa"). Payment of the offer price is being made today to the Weifa shareholders who accepted the voluntary offer and the cash consideration will be available on such shareholders' registered bank accounts in the VPS on or around 9 October 2017. At the same time, 35,453,352 tendered shares are being transferred to Karo Pharma. As a result Karo Pharma now holds 97.21% of the shares and voting rights in Weifa.

Karo Pharma intends to effect a compulsory acquisition of the remaining shares in Weifa at a price equal to the offer price of NOK 35 per share as soon as possible. A separate announcement will be released once the compulsory acquisition has been resolved in accordance with the Norwegian Securities Trading Act section 6-22 cf. the Norwegian Public Limited Companies Act Section 4-25.

For further information, please contact:

Peter Blom, CEO of Karo Pharma, +46 070-655 56 98 or peter.blom@karopharma.se

Simen Nyberg-Hansen, CFO of Weifa: +47 9820 6355, or simen.nyberg-hansen@weifa.no

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via Globenewswire